ArticleYonsei medical journal2016
Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls.
Article in Yonsei medical journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- A novel miR-1291-ERRα-CPT1C axis modulates tumor cell proliferation, metabolism and tumorigenesis.Theranostics · 2020Pooled it
- Epithelial SLC25A20 Deficiency Drives Immunosuppressive Neutrophil Remodeling via ARG1 Palmitoylation to Promote Colorectal Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A systematic DoE approach for optimizing urinary LC-HRMS metabolomics: enhancing reliability in bladder cancer profiling.Analytical and bioanalytical chemistry · 2026Article
- Preclinical Models of Bladder Cancer: Barrier, Metabolic, and Translational Susceptibility.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Serum Trimethylamine-International journal of molecular sciences · 2026Article
- A Comparative Metabolomics Study of Multiple Urological Diseases by Highly Sensitive Dansylation Isotope Labeling LC-MS.International journal of molecular sciences · 2025Article
- Plasma lipidomics for biomarker identification in non-muscle invasive bladder cancer.BMC cancer · 2025Article
- An NMR Metabolomics Analysis Pipeline for Human Neutrophil Samples with Limited Source Material.Metabolites · 2025Article
- TPH1 inhibits bladder tumorigenesis by targeting HIF-1α pathway in bladder cancer.Asian biomedicine : research, reviews and news · 2024Article
- Metabolomics for the diagnosis of bladder cancer: A systematic review.Asian journal of urology · 2024Review
- Metabolic changes preceding bladder cancer occurrence among Korean men: a nested case-control study from the KCPS-II cohort.Cancer & metabolism · 2023Article
- To be or not to be a fat burner, that is the question for cpt1c in cancer cells.Cell death & disease · 2023Review
- Clinical Significance of Carnitine in the Treatment of Cancer: From Traffic to the Regulation.Oxidative medicine and cellular longevity · 2023Review
- Targeting Energy Metabolism in Cancer Treatment.International journal of molecular sciences · 2022Review
- Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy.Frontiers in public health · 2022Article
- Metabolic Flexibility in Canine Mammary Tumors: Implications of the Carnitine System.Animals : an open access journal from MDPI · 2021Article
- A Unique Urinary Metabolic Feature for the Determination of Bladder Cancer, Prostate Cancer, and Renal Cell Carcinoma.Metabolites · 2021Article
- Analysis of Nuclear Encoded Mitochondrial Gene Networks in Cervical Cancer.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Specific Gut Microbiome and Serum Metabolome Changes in Lung Cancer Patients.Frontiers in cellular and infection microbiology · 2021Article
- Non-Coding and Regulatory RNAs as Epigenetic Remodelers of Fatty Acid Homeostasis in Cancer.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
Abstract
purposeOur previous high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry study identified bladder cancer (BCA)-specific urine metabolites, including carnitine, acylcarnitines, and melatonin. The objective of the current study was to determine which metabolic pathways are perturbed in BCA, based on our previously identified urinary metabolome. MATERIALS AND
methodsA total of 135 primary BCA samples and 26 control tissue samples from healthy volunteers were analyzed. The association between specific urinary metabolites and their related encoding genes was analyzed.
resultsSignificant alterations in the carnitine-acylcarnitine and tryptophan metabolic pathways were detected in urine specimens from BCA patients compared to those of healthy controls. The expression of eight genes involved in the carnitine-acylcarnitine metabolic pathway (CPT1A, CPT1B, CPT1C, CPT2, SLC25A20, and CRAT) or tryptophan metabolism (TPH1 and IDO1) was assessed by RT-PCR in our BCA cohort (n=135). CPT1B, CPT1C, SLC25A20, CRAT, TPH1, and IOD1 were significantly downregulated in tumor tissues compared to normal bladder tissues (p<0.05 all) of patients with non-muscle invasive BCA, whereas CPT1B, CPT1C, CRAT, and TPH1 were downregulated in those with muscle invasive BCA (p<0.05), with no changes in IDO1 expression.
conclusionAlterations in the expression of genes associated with the carnitine-acylcarnitine and tryptophan metabolic pathways, which were the most perturbed pathways in BCA, were determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.